Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): March 3,
2017
AzurRx BioPharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-37853
(Commission File
Number)
46-4993860
(IRS Employer
Identification No.)
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York 11226
(Address
of principal executive offices and zip code)
(646) 699-7855
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
March 3, 2017, the board of directors of AzurRx BioPharma, Inc.
(the “Company”) appointed Charles J. Casamento as a
director. Mr. Casamento, age 71, is currently Executive Director
and Principal of The Sage Group, a healthcare advisory group
specializing in mergers, acquisitions, and partnerships between
biotechnology companies and pharmaceutical companies, since 2007.
He was the president and CEO of Osteologix, Inc., a public
biopharmaceutical company developing products for treating
osteoporosis, from 2004 through 2007. From 1999 through 2004, he
served as chairman of the board, president and CEO of Questcor
Pharmaceuticals, Inc. which was subsequently acquired by
Mallinckrodt. Mr. Casamento formerly served as RiboGene,
Inc.’s president, CEO and chairman of the board from 1993
through 1999 until it merged with Cypros to form Questcor. He was
co-founder, president and CEO of Interneuron Pharmaceuticals, Inc.
(Indevus), a biopharmaceutical company, from 1989 until 1993.
Indevus was eventually acquired by Endo. Mr. Casamento has also
held senior management positions at Genzyme Corporation, where he
was senior vice president, pharmaceuticals and biochemicals;
American Hospital Supply, where he was vice president of business
development and strategic planning for the Critical Care Division;
Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr.
Casamento also serves on the Board of Directors of Relmada
Therapeutics, Inc. and International Stem Cell Corporation. He is
Chairman of the Audit Committee at Relmada.
During
his career, he has sat on the boards of ten public companies and
has also been a Director and Vice Chairman of The Catholic Medical
Missions Board, a large not for profit organization providing
health care services to third world countries. He has served as a
guest lecturer at Fordham University and is on the Science Council
of Fordham University. He holds a bachelor’s degree in
Pharmacy from Fordham University and an M.B.A. from Iona College.
We believe that Mr. Casamento’s qualifications to serve on
our Board include his significant experience as chief executive
officer in various life sciences companies and his service on
several other boards, which bring valuable knowledge and insights
to our board.
There
have been no transactions in the past two years to which the
Company or any of its subsidiaries was or is to be a party, in
which Mr. Casamento had, or will have, a direct or indirect
material interest.
Item 9.01
Financial Statement and
Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release dated March 8, 2017.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
Dated:
March 9, 2017
|
AZURRX
BIOPHARMA, INC.
By: /s/ Johan M. (Thijs)
Spoor
Name:
Johan M. (Thijs) Spoor
Title:
President and CEO
|
|
|
|
|